By Sherri Oslick --
Earlier this week the litigation between Teva Pharmaceutical Industries Ltd. and Dr. Reddy's Laboratories Inc. over generic Coreg® was dismissed without costs and without prejudice based on a settlement between the parties.
As we reported previously, the suit was originally filed in the District Court of New Jersey on June 21, 2007 against Dr. Reddy's for infringement of U.S. Patent Nos. 6,699,997 ("Carvedilol," issued March 2, 2004), 6,710,184 ("Crystalline Solids of Carvedilol and Processes for Their Preparation," issued March 23, 2004), 7,056,942 ("Carvedilol," issued June 6, 2006), and 7,126,008 (same title, issued October 24, 2006) based on defendants' filing of an ANDA to manufacture and sell a generic version of GSK's Coreg® (carvedilol, used to treat congestive heart failure and high blood pressure). Dr. Reddy's ANDA was approved by the FDA in September, 2007, at the end of GSK's pediatric exclusivity period.
Comments